Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease

Archives of Neurology

Volumn 56, Issue 10, 1999, Pages 1266-1272

  Lopez, Oscar L ^a,d   Wisniewski, Stephen R ^b   Becker, James T ^a   Boller, François ^c   DeKoshy, Steven T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c CENTRE PAUL BROCA   (France)

^d Neuropsychological Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORAL HYDRATE; CHLORDIAZEPOXIDE; CLORAZEPATE; DESIPRAMINE; DIAZEPAM; DIPHENHYDRAMINE; DOXEPIN; FLUOXETINE; FLURAZEPAM; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; LORAZEPAM; MEPROBAMATE; MESORIDAZINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; PERPHENAZINE; RISPERIDONE; TEMAZEPAM; THIORIDAZINE; TIOTIXENE; TRAZODONE; TRIAZOLAM; TRIFLUOPERAZINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL ARTICLE; COGNITION; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG USE; FEMALE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RATING SCALE; RISK FACTOR;

EID: 0032844231     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.10.1266     Document Type: Article

References (63)

1. Backer JT, Boiler F, Lopez OL, Saxton J, McGonigle K. The natural history of Alzheimer disease: description of study cohort and accuracy of diagnosis. Arch Neuroi 1994;51:585-594.
2. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997:54:257-263.
3. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry. 1989:146:577-587.
4. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989:25:39-48.
5. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: prospective analyses from the Predictors Study. Neurology. 1994:44:2300-2307.
6. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer disease. Arch Neurol. 1994:51:676-681.
7. Lopez OL, Brenner RP, Becker JT, Ulrich RF, Boiler F, DeKosky ST. EEC spectral abnormalities and psychosis as predictors of cognitive and functional decline in probable Alzheimer's disease. Neurology. 1997:48:1521-1525.
8. Walsh JS, Welch HG, Larson EB. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med. 1990;113:429-434.
9. Moritz DJ, Fox PJ, Luscombe FA, Kraemer HC. Neurological and psychiatric predictors of mortality in patients with Alzheimer disease in California. Arch Neurol. 1997:54:878-885.
10. Lopez OL, Boiler F, Becker JT, Miller M, Reynolds CF. Alzheimer's disease and depression: neuropsychological impairment and progression of the illness. Am J Psychiatry. 1990:147:855-860.
11. Burns A, Lewis G, Jacoby R, Levy R. Factors affecting survival in Alzheimer's disease. PsycholMed. 1991:21:363-370.
12. Jagger C, Clarke M, Stone A. Predictors of survival with Alzheimer's disease: a community-based study. PsycholMed. 1995:25:171-177.
13. Wragg RE, Jeste DV. Neuroleptics and alternative treatments. Management of behavioral symptoms and psychosis in Alzheimer's disease and related conditions. Psychiatr Clin North Am. 1988:11:195-213.
14. Semla TP, Cohen D, Freels S, et al. Psychotropic drug use in relation to psychiatric symptoms in community-living persons with Alzheimer's disease. Pharmacotherapy. 1995:15:495-501.
15. Devanand DP, Sackheim HA, Brown RP, Mayeux R. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer disease. Arch Afei/roJ. 1989:46:854-857.
16. Devanand DP. Behavioral complications and their treatment in Alzheimer's disease. Geriatrics. 1997;52(suppl 2):S37-S39.
17. Burke WJ, Dewan V, Wengel SP, Roccaforte WH. Nadolny GC, Folks DG. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia. Int J Geriatr Psychiatry. 1997;12:519-525.
18. Lemke MR. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics. JC/mPsyc/i/afry. 1995:56:354-357.
19. Stern RG, Dyffelmeyer ME, Zemishlani Z, Davidson M. The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatr Clin North Am. 1991:14:375-384.
20. Randels PM, Marco LA, Hanspal NS, Robinson B. Possible lithium-induced extrapyramidal effects in Alzheimer's disease. Hillside J Clin Psychiatry. 1984;6: 117-121.
21. Goad DL, Davis CM, Liem P, Fuselier CC, McCormack JR, Olsen KM. The use of selegiline in Alzheimer's patients with behavioral problems. J Clin Psychiatry. 1991:52:342-345.
22. Gleason RP, Schneider LS. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics. J Clin Psychiatry. 1990;51:115-118.
23. Tariot PfJ, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155:54-61.
24. Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valprpate for agitation in geriatric neuropsychiatrie disorders. Am J Geriatr Psychiatry. 1997:5: 344-351.
25. Weiler PG, Mungas D, Bernick C. Propanolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol. 1988:1:226-230.
26. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicenter study. Br JPsychiatry. 1990:157:894-901.
27. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment of dementia. JAm Geriatr Soc. 1990:38:553-563.
28. Schneider LS, Sobin PB. Non-neuroleptic medications in the management of agitation in Alzheimer's disease and other dementia: a selective review. IntJ Geriatr Psychiatry. 1991;6:691-708.
29. McKhann G, Drachman DA, Folstein MF, Katzman R, Price DL, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984:34:939-944.
30. Hachinski VC, Iliff LD, Zihka E, et al. Cerebral blood flow in dementia. Arch Neurol. 1975:32:632-637.
31. Mezzich JE, Dow JT, Cottman GA. Developing an information system for a comprehensive psychiatric institute, I: principles, design, and organization. Behav Res Methods Instrument. 1981:13:459-463.
32. Lopez OL, Gonzalez MP, Becker JT, Reynolds CF, SudilovskyA, DeKosky ST. Symptoms of depression and psychosis in Alzheimer's disease and frontotemporal dementia. Neuropsychiatry Neuropsychol Behav Neurol. 1996;9:154-161.
33. Kaufer DA, Cummings JL, Christine D. Differential neuropsychiatrie symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci. 1998;10:55-63.
34. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile changes in the cerebral white matter of elderly subjects. BrJ Psychiatry. 1968:114:797-811.
35. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. Psychiatry Res. 1975; 12:189-198.
36. Devanand DP, Jacobs DM, Tang M, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997:54:257-263.
37. Teri L, Larson EB, Reif ler BV. Behavioral disturbance in dementia of the Alzheimer's type. JAm Geriatr Soc. 1988:36:1-6.
38. Hamilton M. A rating scale for depression. J NeurolNeurosurg Psychiatry. 1960; 23:56-62.
39. Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
40. Levy ML, Cummings JL, Fairbanks LA, Bravi D, Calvani M, Carta A. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry. 1996;153:1438-1443.
41. Mendez MF, Martin RJ, Smyth KA, Whitehouse PJ. Psychiatric symptoms associated with Alzheimer's disease. J Neuropsychiat Clin Neurosci. 1990:2:28-33.
42. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease, IV: disorders of behavior. Br J Psychiatry. 1990:157:86-94.
43. Burns A, Jacoby R, Levy R. Psychiatric penomena in Alzheimer's disease, I: disorders of thought content. Br J Psychiatry. 1990:157:72-76.
44. Lopez OL, Becker JT, Brenner RP, Rosen J, Bajulaiye Ol, Reynolds CF. Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology. 1991:41:906-912.
45. Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992;42: 1689-1696.
46. Rovner BW. Depression and increased risk of mortality in the nursing home patient. AmJMed. 1993:94(suppl):19S-22S.
47. Hamel M, Gold DP, Andres D, et al. Predictors and consequences of aggressive behavior by community-based dementia patients. Gerontologist. 1990:30:206-211.
48. Ryden MB. Aggressive behavior in persons with dementia who live in the community. Alzheimer Dis Assoc Disord. 1988:2:342-355.
49. Lieberman MA, Kramer JH. Factors affecting decisions to institutionalize demented elderly. Gerontologist. 1991 ;31:371 -374.
50. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry. 1990; 147:1049-1051.
51. Reifier BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients v/ith and without depression. Am J Psychiatry 1989:146:45-49.
52. Reynolds CF, Perel JM, Kupfer DJ, Zimmer B, Stack JA, Hoch CC. Open-trial response to antidepressant treatment in elderly patients v/ith mixed depression and cognitive impairment. Psychiatry Res. 1987:21:111-122.
53. Teri L, Reifler BV, Veith RC, et al. Imipramine in the treatment of depressed Alzheimer's patients: impact on cognition. J Gerontol. 1991 ;46:P372-P377.
54. Taragano FE, Lyketsos CG, Mangone CA, Aliegri RF, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fiuoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997:38:246-252.
55. Devanand DP, Levy SR. Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol. 1995;8(suppl 1):S18-S27.
56. King DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry. 1990:157:799-811.
57. Curran HV, Bond A, O'Sullivan G, Bruce M, Marks I. Memory functions, alprazolam and exposure therapy: a controlled longitudinal study of agoraphobia with panic disorder. PsycholMed. 1994:24:969-976.
58. Ray WA. Psychotropic drugs and injuries among the elderly: a review. JC/m Psychopharmacol. 1992:12:386-396.
59. Robin DW, Hasan SS, Edeki T, Lichtenstein MJ, Shiavi RG, Wood AJ. Increased baseline sway contributes to increased losses of balance in older people following triazolam. JAm Geriatr Soc. 1996:44:300-304.
60. Wysowski DK, Baum C, Ferguson WJ, Lundin F, Ng MJ, Hammerstrom T. Sedativehypnotic drugs and the risk of hip fracture. J Clin Epidemiol. 1996:49:111-113.
61. Borson S, Raskind MA. Clinical features and pharmacologie treatment of behavioral symptoms of Alzheimer's disease. Neurology. 1997;48{5 suppl 6):S17-S24.
62. Aarsland D, Cummings JL, Yenner G, Miller B. Relationship of aggressive behavior to other neuropsychiatrie symptoms in patients v/ith Alzheimer's disease. Am J Psychiatry. 1996;153:243-247.
63. Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry. 1991;148: 1159-1163.